Literature DB >> 17187665

A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan.

Hon-Chung Fung1, Chiung-Mei Chen, John Hardy, Andrew B Singleton, Yih-Ru Wu.   

Abstract

BACKGROUND: Parkinson's disease (PD) is the most common neurodegenerative movement disorder, characterized clinically by resting tremor, bradykinesia, postural instability and rigidity. The prevalence of PD is approximately 2% of the population over 65 years of age and 1.7 million PD patients (age > or = 55 years) live in China. Recently, a common LRRK2 variant Gly2385Arg was reported in ethnic Chinese PD population in Taiwan. We analyzed the frequency of this variant in our independent PD case-control population of Han Chinese from Taiwan.
METHODS: 305 patients and 176 genetically unrelated healthy controls were examined by neurologists and the diagnosis of PD was based on the published criteria. The region of interest was amplified with standard polymerase chain reaction (PCR). PCR fragments then were directly sequenced in both forward and reverse directions. Differences in genotype frequencies between groups were assessed by the X2 test, while X2 analysis was used to test for the Hardy-Weinberg equilibrium.
RESULTS: Of the 305 patients screened we identified 27 (9%) with heterozygous G2385R variant. This mutation was only found in 1 (0.5%) in our healthy control samples (odds ratio = 16.99, 95% CI: 2.29 to 126.21, p = 0.0002). Sequencing of the entire open reading frame of LRRK2 in G2385R carriers revealed no other variants.
CONCLUSION: These data suggest that the G2385R variant contributes significantly to the etiology of PD in ethnic Han Chinese individuals. With consideration of the enormous and expanding aging Chinese population in mainland China and in Taiwan, this variant is probably the most common known genetic factor for PD worldwide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17187665      PMCID: PMC1764029          DOI: 10.1186/1471-2377-6-47

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


Background

Parkinson's disease (PD) is the most common neurodegenerative movement disorder, characterized clinically by resting tremor, bradykinesia, postural instability and rigidity. The prevalence of PD is approximately 2% of the population over 65 years of age and 1.7 million PD patients (age ≥ 55 years) live in China [1,2]. Mutations in five genes have been shown to cause parkinsonism: α-synuclein (dominant), parkin (recessive), DJ-1 (recessive), PINK1 (recessive) and LRRK2 (dominant) [3]. Since LRRK2 mutation has been reported as a cause of PD, a number of LRRK2 substitutions have been identified to be pathogenic [4]. To date, the most common genetic variant underlying sporadic PD is the G2019S variant reported at up to 40% frequencies in different Caucasian populations [5]. The genotype-phenotype correlations have been studies on this mutation [6]. The clinical manifestations of the G2019S carriers closely resemble those of typical PD with pleomorphic pathological findings [7,8]. The rarity of the G2019S mutation in Chinese population suggests the occurrence of this mutation resulted from a common European founder [9]. Recently, a common variant Gly2385Arg was reported in ethnic Chinese PD population in Taiwan [10,11]. In this study, we analyzed the frequency of this variant in our independent PD case-control population of Han Chinese from Taiwan and explore the genotype-phenotype correlations of this prevalent alteration in our Taiwanese PD cohort.

Methods

Subjects

305 patients with sporadic idiopathic PD (46% Female, Mean age of onset: 61.8 ± 10.6 years, Range: 30–91 years) were selected from the neurology clinic of Chang-Gung Memorial Hospital. 176 unrelated healthy adult volunteers (46% female, Mean Age at exam: 59.6 ± 9.6 years, Range: 38–86 years) were matched for ethnic origin and area of residence. These normal control individuals are genetically unrelated to the individuals in the patient group. All patients were examined by a neurologist (YR Wu or CM Chen), and the diagnosis of PD was based on the published criteria [12]. Patients with evidence of secondary parkinsonism or with atypical features such as early dementia, ophthalmoplegia, early autonomic failure, and pyramidal signs were not included in this study. All examinations were performed after obtaining informed consent under a protocol approved by the internal ethics and scientific boards of National Institutes of Health.

Genotyping and statistical analysis

Genomic DNA was extracted from peripheral blood using standard protocols. The region of interest was polymerase chain reaction (PCR)-amplified as previously described. Assay of the G7153A polymorphism in all the individuals was performed by PCR amplification with primer pair 5'-ATGCAGCTTTCAGTGATTCCA-3' (forward) and 5'-TCTGAAAAGATGGTGCTGAGAAG-3' (reverse). Cycle sequencing in forward and reverse directions was performed on purified PCR products with the Big Dye Terminator chemistry and run on an ABI 3100 automated DNA sequencer. (Applied Biosystems, Foster City, CA). Differences in genotype frequencies between groups were assessed by the X2 test. X2 analysis was used to test for the Hardy-Weinberg equilibrium (HWE).

Results

Of the 305 patients screened we identified 27 (9%) with heterozygous for the G2385R variant. This mutation was only found in 1 (0.5%) in our healthy control samples (odds ratio = 16.99, 95% CI: 2.29 to 126.21, p = 0.0002). In both groups, there were no deviations from HWE at this G7153A locus. None of the patients with the 2385R variant had a family history of PD. Age of onset for the 2385R carriers was 33–79 years (mean 61.5 ± 11.3 years). Meanwhile, age of onset of 285 PD cases without the 2385R variant was 31–91 years (mean 61.9 ± 10.5 years). Sequencing of the entire open reading frame and flanking intronic sequence (>50 bp) of LRRK2 in 2385R carriers revealed no other coding variants. The clinical presentations of all G2385R carriers showed no difference from typical idiopathic PD with definite asymmetric onset, bradykinesia, resting tremor (4–6 Hz), rigidity (Table 1). All carriers showed response to dopamine replacement therapy based on clinical observation.
Table 1

Comparison of clinical manifestations between PD 2385R carriers and PD non 2385 carriers

PD (2385R Carrier)PD(Non 2385R Carrier)
Number of subject27278
Age of Onset(Mean ± SD)61.5 ± 11.361.9 ± 10.5
Resting tremor (n, %)26(96)252 (88)
Bradykinesis (n, %)27(100)269 (97)
Rigidity (n, %)26(96)261(94)
Asymmetrical onset (n, %)20(74)203(73)

PD: Parkinson disease

Discussion

LRRK2, encodes a protein called dardarin that is postulated as a member of the ROCO protein family. There are five conserved domains in this protein. The LRRK2 kinase domain belongs to the MAPKKK subfamily of kinases. The active sites of all kinases are located in a cleft between an N-terminal and a C-terminal lobe, typically covered by an activation loop in an inactive confirmation. The residue G2385 substitution lies in the WD40 domain. WD40 domain is speculated to be capable of of mediating protein-protein interactions [13]. Hypothetically, LRRK2 G2385R variant may cause a conformational change of the WD40 domain of LRRK2. The functional effects of the G2385R substitution on dardarin have yet to be established. The lack of the G2385 variant in other populations, except ethnic Chinese PD populations, highlights the fact that the contribution of different genetic factors varies amongst different populations [11]. Furthermore, these discrepancies between mutation frequencies across different ethnicities worldwide lend support to the hypothesis of a founder effect. Our findings delineate LRRK2-related disease as a common form of sporadic PD in the Chinese population. Based on our results, the G2385R variant contributes significantly to the etiology of PD in ethnic Han Chinese individuals. With consideration of the enormous and expanding aging Chinese population in mainland China and in Taiwan, this genetic variant is probably the most common known genetic risk factor for PD worldwide. A routine testing for this mutation at least in our population may be cost-effective. Though whether our finding extends to other Asian populations needs further verification. Complete analysis of the entire 51 exons of LRRK2 will be warranted before recommendations and guidelines for screening of LRRK2 in other ethnic PD patients for diagnostic purposes and genetic counselling be implemented globally.

Conclusion

In conclusion, our data suggest that the G2385R variant contributes significantly to the etiology of PD in ethnic Han Chinese individuals. With consideration of the enormous and expanding aging Chinese population in mainland China and in Taiwan, this variant is probably the most common known genetic factor for PD worldwide.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

HCF carried out the molecular genetic studies participated in the sequence alignment and drafted the manuscript. CMC and YRW participate in the design of the study and collection of data. JH participated in the study, and participated in its design and coordination. ABS conceived of the study and a critical review of the manuscript. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:
  13 in total

1.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

2.  LRRK2 mutations in Parkinson disease.

Authors:  M Farrer; J Stone; I F Mata; S Lincoln; J Kachergus; M Hulihan; K J Strain; D M Maraganore
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

3.  Prevalence of Parkinson's disease in China.

Authors:  Walter A Rocca
Journal:  Lancet Neurol       Date:  2005-06       Impact factor: 44.182

4.  The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.

Authors:  E K Tan; Y Zhao; L Skipper; M G Tan; A Di Fonzo; L Sun; S Fook-Chong; S Tang; E Chua; Y Yuen; L Tan; R Pavanni; M C Wong; P Kolatkar; C S Lu; V Bonifati; J J Liu
Journal:  Hum Genet       Date:  2006-09-30       Impact factor: 4.132

5.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China.

Authors:  Zhen-Xin Zhang; Dallas W Anderson; Jue-Bin Huang; Hui Li; Xia Hong; Jing Wei; En-Li Yang; Demetrius M Maraganore
Journal:  Mov Disord       Date:  2003-07       Impact factor: 10.338

8.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

9.  Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease.

Authors:  Hon-Chung Fung; Chiung-Mei Chen; John Hardy; Dena Hernandez; Andrew Singleton; Yih-Ru Wu
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  28 in total

1.  Parkinson's disease in China.

Authors:  You-yong Tian; Cui-ju Tang; Jie Wu; Jun-shan Zhou
Journal:  Neurol Sci       Date:  2010-12-14       Impact factor: 3.307

2.  LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients.

Authors:  Daniel Kam Yin Chan; Ping Wing Ng; Vincent Mok; Jonas Yeung; Zhi Ming Fang; Raymond Clarke; Edward Leung; Lawrence Wong
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

3.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Authors:  Iakov N Rudenko; Alice Kaganovich; David N Hauser; Aleksandra Beylina; Ruth Chia; Jinhui Ding; Dragan Maric; Howard Jaffe; Mark R Cookson
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

Review 4.  Genetics of Parkinson disease and essential tremor.

Authors:  Christian Wider; Owen A Ross; Zbigniew K Wszolek
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

Review 5.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 6.  The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies.

Authors:  Cheng-Long Xie; Jia-Lin Pan; Wen-Wen Wang; Yu Zhang; Su-Fang Zhang; Jing Gan; Zhen-Guo Liu
Journal:  Neurol Sci       Date:  2014-07-16       Impact factor: 3.307

Review 7.  LRRK2 pathobiology in Parkinson's disease.

Authors:  Ian Martin; Jungwoo Wren Kim; Valina L Dawson; Ted M Dawson
Journal:  J Neurochem       Date:  2014-10-10       Impact factor: 5.372

8.  LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Angelica Marsberg; Rowena Keyser; Debbie Lombard; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  J Neural Transm (Vienna)       Date:  2010-06-11       Impact factor: 3.575

9.  LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation.

Authors:  Chao Gao; Hao Pang; Xiao-Guang Luo; Yan Ren; Hong Shang; Zhi-Yi He
Journal:  J Neurol       Date:  2013-08-30       Impact factor: 4.849

10.  Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Authors:  K Haugarvoll; R Rademakers; J M Kachergus; K Nuytemans; O A Ross; J M Gibson; E-K Tan; C Gaig; E Tolosa; S Goldwurm; M Guidi; G Riboldazzi; L Brown; U Walter; R Benecke; D Berg; T Gasser; J Theuns; P Pals; P Cras; P Paul De Deyn; S Engelborghs; B Pickut; R J Uitti; T Foroud; W C Nichols; J Hagenah; C Klein; A Samii; C P Zabetian; V Bonifati; C Van Broeckhoven; M J Farrer; Z K Wszolek
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.